Johan Juhlin, CEO & Co-Founder, Mavatar Johan Juhlin is a seasoned entrepreneur and healthcare innovator with over 25 years of experience in the medical field, including senior leadership roles in major diagnostic & pharmaceutical companies. As the former Nordic Commercial Director at Ventana Medical Inc., he played a pivotal role in the launch of the HER2 marker for breast cancer, on a diagnostic platform. The marker achieved rapid adoption—used by 12% of patients in its first year and reaching an impressive 94% penetration within two years. By 2020, HER2 had grown into a $10.4 billion market. As the CEO and co-founder of Mavatar, Johan is driving a new era of AI-powered precision medicine. Mavatar is redefining the future of healthcare by leveraging medical avatars and artificial intelligence to accelerate drug development, optimize clinical trials, and deliver hyper-personalized treatment plans. With his proven track record of scaling groundbreaking medical innovations, Juhlin is poised to lead Mavatar toward transforming patient care on a global scale.